Effective Treatment of Colq-Deficient Mice with Adeno-Associated Virus Type Rh74-Mediated Gene Therapy.

Abstract

Mutations in human, which encodes the collagen-like tail subunit (ColQ) of asymmetrical acetylcholinesterase (AChE), cause congenital myasthenic syndrome (CMS) with deficiency of end plate AChE. A valuable animal model of-CMS is the Colq-deficient () mouse, which lacks asymmetrical AChE in skeletal and cardiac muscles. Mutantmice fail to thrive, and many die before reaching maturity. With the aim of developing a treatment for-CMS,mice were injected at postnatal day 26-29 with three doses of an adeno-associated virus type rh74 carrying full-length human(AAVrh74-): 5 &#xd7; 10viral genomes per kilogram (vg/kg) (intravenously [IV]), 1 &#xd7; 10vg/kg (IV), and 2 &#xd7; 10vg/kg (1 &#xd7; 10vg/kg IV + 1 &#xd7; 10vg/kg intraperitoneally). Motor performance was evaluated using rotarod, grip strength, and wire hang tests weekly for 12 weeks. Voluntary ambulation and repetitive nerve stimulation (RNS) were assessed once before euthanasia. Protein and RNA expression of COLQ was measured via immunohistochemistry (IHC) and reverse transcriptase quantitative PCR (RT-qPCR), respectively. Mice treated with AAVrh74-at 1 &#xd7; 10and 2 &#xd7; 10vg/kg doses showed 100% survival and no adverse side effects. Mice injected with 2 &#xd7; 10vg/kg showed almost full recovery and similar scores to wild type that were significantly higher than vehicle-injected mutants for grip strength (value <0.0001), rotarod (value <0.0001), and RNS (value <0.0001). Similar improvements were observed in mice injected with 1 &#xd7; 10vg/kg, although the recovery of grip strength was incomplete. Mice injected with 5 &#xd7; 10vg/kg showed incomplete recovery. IHC demonstrated full recovery of protein expression in 1 &#xd7; 10and 2 &#xd7; 10vg/kg mice, and RT-qPCR unambiguously demonstrated that the source of the ColQ was humanIn summary, a single treatment of AAVrh74-(1 &#xd7; 10to 2 &#xd7; 10vg/kg) was effective and safe formice, which reproduce many of the clinical features of the human-CMS phenotype. Thus, these results support a similar therapy for patients affected with-CMS.